(466a) Use of Site Specific Recombinases to Engineer New Cell Lines for Therapeutic Protein Biomanufacturing
AIChE Annual Meeting
2017
2017 Annual Meeting
Food, Pharmaceutical & Bioengineering Division
Cell Culture Engineering & Process Design I: Cell Systems Engineering
Wednesday, November 1, 2017 - 8:00am to 8:18am
By RMCE, new cell lines producing TNFR:Fc fusion protein or Erythropoietin were generated from the template cell line. First, we optimized the use of RMCE by performing recombination transiently between plasmids to determine the optimal donor DNA to recombinase ratio. Then, using this information, we generated pools of cells with new product genes. The pools were then subcloned to characterize the variation between cells that have had targeted integration of a new product gene. We compared the productivity, transcript levels, and growth of different clones to identify the potential for RMCE to replace traditional cell line development. If a high producing cell line can be changed to produce a new product gene and maintain its productivity, we could vastly improve the cell line development process by shortening the time to obtain a high producing, stable cell line.